Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) continues to make significant progress with its Cologuard test and efforts to expand Oncotype DX overseas. Advancements in the key pipeline programs are highly promising. The stock carries a Zacks Rank #2 (Buy) currently.Exact Sciences is focusing on three areas to enhance its flagship Cologuard’s growth. The first is to build the best and most effective commercial organization in healthcare by investing in the leadership team, training, and sales force effectiveness. Second, it intend ...